Five Years of Sacubitril/Valsartan —a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance
ConclusionWith increased uptake of sacubitril/valsartan, risks of hypotension, renal dysfunction, hyperkalemia, and angioedema appear low and acceptable in RCTs and global clinical practice.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Databases & Libraries | Diovan | Heart | Heart Failure | Statistics | Study